Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Dose-Escalating, P-C, D-B, Parallel Group Study in HIV Treatment-Experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days (PART B).

Next Previous
X
Search
Trial Profile

Phase 2 Dose-Escalating, P-C, D-B, Parallel Group Study in HIV Treatment-Experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days (PART B).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevirimat (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Sponsors Panacos Pharmaceuticals

    • Most Recent Events

    • 22 Jan 2010 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 03 Jul 2009 Additional lead trial centre (Myriad Pharmaceuticals) identified as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Phase IIb data reported at ICAAC/IDSA 2008, according to a Panacos media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top